Valeant Pharmaceuticals International, Inc. (TSE:VRX) (NYSE:VRX) shares traded up 2.8% on Monday . The company traded as high as C$18.87 and last traded at C$18.80. 1,068,220 shares were traded during mid-day trading, a decline of 25% from the average session volume of 1,430,540 shares. The stock had previously closed at C$18.28.

Several brokerages recently commented on VRX. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a C$23.00 price objective on shares of Valeant Pharmaceuticals International in a research note on Wednesday, November 8th. TD Securities raised Valeant Pharmaceuticals International from a “hold” rating to a “buy” rating and set a C$25.50 price objective on the stock in a research note on Wednesday, November 8th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Valeant Pharmaceuticals International has an average rating of “Hold” and a consensus price target of C$22.50.

ILLEGAL ACTIVITY WARNING: “Valeant Pharmaceuticals International, Inc. (VRX) Trading 2.8% Higher” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.